NOX 2.86% 7.2¢ noxopharm limited

Novartis Vision trial result, page-11

  1. 1,610 Posts.
    lightbulb Created with Sketch. 409
    Thanks, though Graham seems to agree with my proposition:

    "The VISION study compared Lu-PSMA-617 with standard of care in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received at least two previous lines of therapy ...This compares with the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda in men with end-stage mCRPC who had progressed on at least three previous lines of therapy."

    (from today's announcement; my emphasis)
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.